JP6411215B2 - 虚血傷害を治療するためのシステアミンおよび／またはシスタミン - Google Patents

虚血傷害を治療するためのシステアミンおよび／またはシスタミン Download PDF

Info

Publication number
JP6411215B2
JP6411215B2 JP2014542590A JP2014542590A JP6411215B2 JP 6411215 B2 JP6411215 B2 JP 6411215B2 JP 2014542590 A JP2014542590 A JP 2014542590A JP 2014542590 A JP2014542590 A JP 2014542590A JP 6411215 B2 JP6411215 B2 JP 6411215B2
Authority
JP
Japan
Prior art keywords
cysteamine
adiponectin
subject
cystamine
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014542590A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014533701A5 (enExample
JP2014533701A (ja
Inventor
ドヒル，ランジャン
フィリップス，スーザン，エー．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California Berkeley
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2014533701A publication Critical patent/JP2014533701A/ja
Publication of JP2014533701A5 publication Critical patent/JP2014533701A5/ja
Application granted granted Critical
Publication of JP6411215B2 publication Critical patent/JP6411215B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2014542590A 2011-11-22 2012-11-21 虚血傷害を治療するためのシステアミンおよび／またはシスタミン Expired - Fee Related JP6411215B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161563034P 2011-11-22 2011-11-22
US61/563,034 2011-11-22
PCT/US2012/066288 WO2013078335A1 (en) 2011-11-22 2012-11-21 Cysteamine and/or cystamine for treating ischemic injury

Publications (3)

Publication Number Publication Date
JP2014533701A JP2014533701A (ja) 2014-12-15
JP2014533701A5 JP2014533701A5 (enExample) 2016-01-21
JP6411215B2 true JP6411215B2 (ja) 2018-10-24

Family

ID=47297472

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014542590A Expired - Fee Related JP6411215B2 (ja) 2011-11-22 2012-11-21 虚血傷害を治療するためのシステアミンおよび／またはシスタミン

Country Status (16)

Country Link
US (1) US20140322315A1 (enExample)
EP (1) EP2782564B1 (enExample)
JP (1) JP6411215B2 (enExample)
KR (1) KR20140097132A (enExample)
CN (2) CN103974698A (enExample)
AU (1) AU2012340670B2 (enExample)
BR (1) BR112014012167A2 (enExample)
CA (1) CA2851387A1 (enExample)
HK (1) HK1202440A1 (enExample)
IL (1) IL232608A0 (enExample)
MX (1) MX2014004469A (enExample)
MY (1) MY165953A (enExample)
RU (1) RU2638807C2 (enExample)
SG (2) SG11201402472QA (enExample)
WO (1) WO2013078335A1 (enExample)
ZA (1) ZA201402290B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR096628A1 (es) * 2013-06-17 2016-01-20 Raptor Pharmaceuticals Inc Formulación en perlas de cisteamina de liberación retardada y métodos de preparación y uso de ella
TWI759267B (zh) 2015-07-02 2022-04-01 美商地平線罕見醫學製藥有限責任公司 Ａｄｏ抗性半胱胺類似物及其用途
CN106591461A (zh) * 2016-12-29 2017-04-26 天津协和华美医学诊断技术有限公司 一种检测遗传性易栓症相关基因群的检测试剂盒
CN110392568A (zh) 2017-01-19 2019-10-29 耳科制药公司 N-乙酰半胱氨酸的制剂及其用途
MX2019008847A (es) * 2017-01-25 2019-12-16 Adare Pharmaceuticals Inc Profarmacos de cisteamina.
WO2021022012A1 (en) * 2019-07-30 2021-02-04 The Regents Of The University Of California Methods and composition for treating respiratory obstructive diseases
CN113484453B (zh) * 2021-07-07 2022-08-09 天津中医药大学 一种缺血性脑卒中预警方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809918A (en) 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
DE2010416B2 (de) 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
FR2471186A1 (fr) 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4301146A (en) 1980-07-29 1981-11-17 G. D. Searle & Co. Stabilization of 16-oxygenated prostanoic acid derivatives
FR2549051B1 (fr) 1983-06-22 1986-05-16 Centre Nat Rech Scient Nouveaux agents radioprotecteurs ayant une structure amino-thioalkyle et procede pour leur preparation
FR2573077B1 (fr) * 1984-11-13 1987-02-13 Sanofi Sa Nouveaux derives thiosulfonates, leur procede de preparation ainsi que les compositions pharmaceutiques les contenant
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
KR890004692A (ko) * 1987-09-08 1989-05-09 스야마 타다카즈 혈소판 응지억제제
JPH02243619A (ja) * 1989-03-15 1990-09-27 Green Cross Corp:The 抗血小板凝集剤
SK232890A3 (en) 1989-05-17 1998-11-04 Pfizer 2-piperidino and 2-pyrrolidino-1-alkanols derivatives and preparation method thereof
US5225202A (en) 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
US5436255A (en) 1992-07-23 1995-07-25 Pfizer Inc. Method of treating diseases susceptable to treatment by blocking NMDA-receptors
TW281670B (enExample) 1993-09-02 1996-07-21 Hoffmann La Roche
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610736B (en) 1995-12-22 1997-06-27 Warner Lambert Co 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
WO1997023202A1 (en) 1995-12-22 1997-07-03 STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALTH SCIENCES UNIVERSITYA ND THE UNIVERSITY OF OREGON, EUGENE OREGON Subtype-selective nmda receptor ligands and the use thereof
ZA9610745B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
US6087398A (en) * 1996-03-01 2000-07-11 South Alabama Medical Science Foundation Sickle cell anemia treatment
FR2753098B1 (fr) * 1996-09-06 1998-11-27 Sod Conseils Rech Applic Composition pharmaceutique comprenant au moins un inhibiteur de no synthase et au moins un piegeur des formes reactives de l'oxygene
DE19643790A1 (de) 1996-10-30 1998-05-07 Merck Patent Gmbh Benzoxazol-Derivat
NZ502785A (en) 1997-10-24 2003-03-28 Warner Lambert Co Use of NR1A/2B site-selective NMDA receptor antagonist compounds for treating disease-related or drug-induced dyskinesias
PE20000728A1 (es) 1998-06-26 2000-08-21 Cocensys Inc Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
AU1808100A (en) 1998-10-28 2000-05-15 Vitaly V. Romanenko Electrodynamic particle size analyzer
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
US6316474B1 (en) 1999-10-29 2001-11-13 Merck & Co., Inc. 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
US6432976B1 (en) 1999-10-29 2002-08-13 Merck & Co., Inc. 8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists
WO2001030330A2 (en) 1999-10-29 2001-05-03 Merck Sharp & Dohme Limited Method to treat pain utilizing benzimidazole nmda/nr2b antagonists
US6369076B1 (en) 1999-10-29 2002-04-09 Merck & Co. Inc. 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists
US6489477B1 (en) 1999-10-29 2002-12-03 Merck & Co., Inc. 2-aza-bicyclo[2.2.2]octane NMDA/NR2B antigonists
US6291499B1 (en) 1999-10-29 2001-09-18 Merck & Co., Inc. 2-cyclohexyl benzimidazole NMDA/NR2B antagonists
ATE515261T1 (de) * 2003-12-19 2011-07-15 Omega Bio Pharma Ip3 Ltd Zusammensetzungen zur behandlung von diabetes
CN1976691B (zh) * 2004-05-03 2010-10-13 奥加生物药业(I.P.3)有限公司 半胱胺用于治疗高胆固醇血症和糖尿病并发症
EP2214480B1 (en) * 2007-11-30 2013-03-27 The Regents of the University of California Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products
RU2428192C1 (ru) * 2010-06-10 2011-09-10 Войсковая Часть 41598 Радиозащитное средство

Also Published As

Publication number Publication date
CN103974698A (zh) 2014-08-06
CA2851387A1 (en) 2013-05-30
US20140322315A1 (en) 2014-10-30
RU2014125282A (ru) 2015-12-27
HK1202440A1 (zh) 2015-10-02
MY165953A (en) 2018-05-18
AU2012340670A1 (en) 2014-04-17
EP2782564B1 (en) 2019-01-09
BR112014012167A2 (pt) 2017-05-30
CN108042517A (zh) 2018-05-18
WO2013078335A1 (en) 2013-05-30
SG11201402472QA (en) 2014-06-27
MX2014004469A (es) 2014-08-01
IL232608A0 (en) 2014-06-30
ZA201402290B (en) 2017-06-28
KR20140097132A (ko) 2014-08-06
SG10201800159QA (en) 2018-02-27
RU2638807C2 (ru) 2017-12-15
AU2012340670B2 (en) 2016-12-22
JP2014533701A (ja) 2014-12-15
EP2782564A1 (en) 2014-10-01

Similar Documents

Publication Publication Date Title
JP6411215B2 (ja) 虚血傷害を治療するためのシステアミンおよび／またはシスタミン
JP7629049B2 (ja) 貧血治療のための組成物及び方法
KR102462275B1 (ko) 산소화 콜레스테롤 술페이트, 및 폴리알킬렌 글리콜, 카르복시메틸 셀룰로오스 및 폴리옥실글리세리드 중 적어도 하나를 포함하는 조성물
KR20190035776A (ko) 5-콜레스텐-3, 25-디올, 3-술페이트 (25hc3s) 또는 이의 약학적으로 허용 가능한 염, 및 적어도 하나의 시클릭 올리고당을 포함하는 조성물
EA010295B1 (ru) Соединения амфетамина с пониженной способностью вызывать злоупотребление ими
JP2011522876A (ja) 永続性心房細動を予防するためのドロネダロン
WO2012096411A1 (ja) 難治性炎症性腸疾患の予防又は治療方法
JP2020500164A (ja) テルリプレシン組成物およびその使用方法
JP2024133735A (ja) Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物
CN104324024A (zh) 心房纤颤的治疗
JP6743001B2 (ja) シス−クロミフェンを用いたアンドロゲン除去療法によって生じるホットフラッシュ及び骨量減少の治療
JP2014526518A (ja) 心不全またはニューロン損傷を治療するための化合物およびその方法
JP2006514665A (ja) 慢性心不全および／または上昇したコレステロールレベルを処置するための方法
TW200536546A (en) A method for the prevention of thrombotic, embolic and/or hemorrhagic disorders
KR20120089623A (ko) 정맥내 투여용 이부프로펜을 이용한 환자의 치료
US20250134864A1 (en) Methods of weight loss and preserving skeletal muscle mass
WO2022199551A1 (en) Dc009 for treating acute ischemic stroke
JP2003527420A (ja) 鬱血性心不全の治療方法
JP2024503377A (ja) バダデュスタットを使用した治療方法
WO2025128432A1 (en) Istaroxime and metabolite derivatives thereof for reducing the risk of acute myocardial arrhythmia
JP2023542743A (ja) 脳卒中の処置

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20141117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20141117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151120

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160810

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160823

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170523

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180320

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180720

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180803

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180904

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180926

R150 Certificate of patent or registration of utility model

Ref document number: 6411215

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees